THER — Theralink Technologies Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $22.59m
- $0.61m
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say (updated)
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say
Brief: Theralink Technologies Appoints Faith Zaslavsky As President, COO
Brief: Theralink Technologies Appoints Mattia Cremona As Director Of Its Biopharma Laboratory
Brief: Oncbiomune Announces Former Puma Biotechnology Executive And Genentech Veteran Brian Barnett, M.D., As Chief Executive Officer
Brief: Oncbiomune awaits approval from regulatory committee to commence phase 2 trial of proscavax
Brief: Oncbiomune to become exclusive distributor of lipomed drugs in Mexico
Brief: OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico
Brief: OncBioMune broadens portfolio, partners and product with Vitel acquisition
Brief: Oncbiomune signs term sheet to acquire Vitel Laboratorios, S.A. De C.V.
Brief: OncBioMune submits protocol for two phase 2 clinical trials